GEMCITABINE TEVA® CONCENTRATE is indicated for the palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-FU refractory pancreatic cancer.GEMCITABINE TEVA® CONCENTRATE is indicated for the treatment of patients with bladder cancer at the invasive stage.Breast cancer:GEMCITABINE TEVA® CONCENTRATE in combination with paclitaxel,is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant /neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.Ovarian cancer:GEMCITABINE TEVA® CONCENTRATE in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma who have relapsed at least 6 months after platinum-based therapy.